Degarelix vs standard androgen suppression therapy
Cancer‐specific survival (24 months) (Number of cancer‐related deaths) · hormone‐sensitive prostate cancer
The review found no eligible studies for this question.
1 finding from 1 review
- Degarelix for treating advanced hormone‐sensitive prostate cancer 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found